Clarius Ultrasound Scanner
Clarius Mobile Health Corp. • Radiology • 05/14/2018
Device Purpose
The Clarius Ultrasound Scanner is a portable diagnostic ultrasound system designed to provide high-resolution, real-time imaging and fluid flow analysis by utilizing wireless transducer technology that interfaces with standard mobile devices. Its methodology leverages piezoelectric principles for image acquisition across multiple modes (including B-mode, Color Doppler, and the newly added Power Doppler) and various transducer types (including a new endocavitary model) to support a broad range of clinical applications, from general imaging to specialized procedures like trans-vaginal exams and needle guidance.
Summary
The Clarius Ultrasound Scanner is a portable, software-controlled diagnostic ultrasound system designed for acquiring and displaying high-resolution, real-time ultrasound images and performing fluid flow analysis. The system utilizes a series of wireless transducers that communicate via Wi-Fi and Bluetooth with off-the-shelf iOS or Android mobile devices, which serve as the display and control interface. This design aims to provide a versatile, easy-to-use, and low-cost ultrasound platform suitable for various clinical and teaching applications, including use in professional healthcare facilities and emergency medical service environments by trained medical professionals. The system includes multiple transducer types (Convex C3, C7; Linear L7; Endocavitary EC7) and accessories like battery packs and chargers, emphasizing its portability and adaptability. The core technology relies on piezoelectric materials within the transducers to transmit high-frequency, non-ionizing sound waves into the body and convert the returning echoes into electronic signals, which are then processed to construct images. These images are wirelessly transmitted to a compatible mobile device for display and analysis. The Clarius Ultrasound Scanner supports multiple imaging modes, including B-mode, M-mode, Color Doppler, Power Doppler, and Pulsed Wave Doppler, along with combined modes and needle enhancement features for procedural guidance. This specific iteration notably expands upon previous versions by adding Power Doppler as a mode of operation and introducing the EC7 endocavitary scanner, which enables new trans-rectal and trans-vaginal diagnostic applications, further broadening its clinical utility across fields such as ophthalmic, fetal, abdominal, pediatric, cardiac, musculoskeletal, and vascular imaging.
AI Regulatory Concerns
Powered by
Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.
Keywords
Device Metadata
Relevant Clinical Questions
- Q1. What is the typical battery life of the wireless transducers during continuous operation in various imaging modes (e.g., B-mode vs. Power Doppler), and how does it impact usability in extended emergency or remote settings?; How does the image quality and diagnostic accuracy of the Clarius Ultrasound Scanner, particularly with the new Power Doppler mode and EC7 endocavitary transducer, compare to traditional, cart-based ultrasound systems in specific clinical applications like trans-vaginal or small organ imaging?; What are the specific technical specifications (e.g., frequency range, penetration depth, resolution) for each transducer model (C3, C7, L7, EC7), and how do these influence their suitability for the diverse range of indicated uses?; Considering the reliance on Wi-Fi Direct for communication, what security measures are implemented within the Clarius Ultrasound App and transducer firmware to ensure patient data privacy and protect against unauthorized access or interference, especially in multi-user environments?; What quantitative data supports the "high-performance" and "low-cost" claims for this ultrasound platform, particularly concerning its performance in challenging diagnostic scenarios or its total cost of ownership compared to predicate devices or other portable ultrasound systems?
Risk Classification
ESL AnalysisFDA Class II via 510(k) pathway; IEC 62304 Class B (software safety classification); Authorized before §524B enforcement
Learn how Parasoft automates IEC 62304 compliance testing →Cybersecurity Evidence
Powered by SBOMator™Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.
Supply Chain BOM Evidence
Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.
Analysis:
• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.
• Evidence of SaaSBOM, HBOM, OBOM detected in AI-generated device summary.
• This device was authorized before §524B took effect. Cybersecurity evidence requirements were less prescriptive at the time.
• Postmarket cybersecurity monitoring plan not clearly documented in AI-generated device summary.
• Not detected in AI-generated device summary: SBOM, ML-BOM, CBOM, VDR/VEX. These may be present in the full FDA submission.
Preparing a similar submission?
ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.
Assess Your Readiness →Or contact ESL directly